UK Markets closed
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • FTSE 250

    20,372.52
    +123.78 (+0.61%)
     
  • AIM

    968.25
    +10.25 (+1.07%)
     
  • GBP/EUR

    1.1764
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.2021%)
     
  • BTC-GBP

    22,855.96
    -220.36 (-0.95%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • DOW

    33,212.96
    +575.77 (+1.76%)
     
  • CRUDE OIL

    115.07
    +0.98 (+0.86%)
     
  • GOLD FUTURES

    1,857.30
    +3.40 (+0.18%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • HANG SENG

    20,697.36
    +581.16 (+2.89%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • CAC 40

    6,515.75
    +105.17 (+1.64%)
     

Worldwide TCV Vaccines Industry to 2030 - Featuring GlaxoSmithKline, Sanofi and Bharat Biotech Among Others

·6-min read
Company Logo
Company Logo

TCV Vaccines Market

TCV Vaccines Market
TCV Vaccines Market

Dublin, April 18, 2022 (GLOBE NEWSWIRE) -- The "TCV Vaccines Market, by Vaccine Brand, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Typbar TCV vaccine is a typhoid vaccine recommended for the prevention of typhoid fever. Typbar TCV vaccine works by causing the body to produce its own protection (antibodies) against the bacteria. This vaccine is generally recommended for individuals who are traveling to areas where typhoid fever is common.

Ongoing Typbar-TCV studies will provide important data of great value to typhoid-fever-endemic regions, and for incorporation of the vaccine into routine immunization programs in endemic regions such as Asia, Latin America and others to control drug-resistant typhoid fever and the spread of antimicrobial resistance globally. World Health Organization recommends the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in typhoid-endemic countries.

This new policy help and ensure access to typhoid vaccination in communities most impacted by the disease, which is responsible for nearly 12 million infections and between 128,000 and 161,000 deaths a year. Typhoid disproportionally impacts young children and marginalized populations in much of Asia Pacific, Sub-Saharan Africa, and parts of Latin America and the Middle East that often have outdated, inadequate, or unsafe water and sanitation systems. With supportive global and financial policies in place, typhoid vaccines, in addition to water, sanitation, and hygiene interventions, can reach those who need them most and reduce the burden of typhoid fever.

Market Dynamics

Increasing prevalence of typhoid, increasing government initiatives promoting and advancing the development of innovative products, increasing antibiotic resistance and adoption of inorganic growth strategies such as collaboration and agreement, in order to expand their product portfolio and strengthen their presence in the market. These are the major factors expected to drive the growth of global TCV vaccines market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global TCV vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

  • It profiles key players in the global TCV vaccines market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

  • Key companies covered as a part of this study include GlaxoSmithKline PLC, Sanofi SA, Bharat Biotech, PT BIO FARMA, and PaxVax, Inc.

  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

  • The global TCV vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global TCV vaccines market

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Purview

  • Report Description

  • Market Definition and Scope

  • Executive Summary

  • Market Snippet, By Vaccine Brand

  • Market Snippet, By Distribution Channel

  • Market Snippet, By Region

  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics

  • Drivers

  • Restraints

  • Market Opportunities

  • Impact Analysis

  • Pipeline Analysis

  • PEST Analysis

  • Regulatory Scenario

  • Market Trends

  • Key Highlights

  • Reimbursement Scenario

  • Mergers & Acquisitions

4. Global TCV Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

  • Economic Impact

  • Government Initiatives

5. Global TCV Vaccines Market, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Introduction

  • Market Share Analysis, 2022 and 2030 (%)

  • Y-o-Y Growth Analysis, 2018 - 2030

  • Segment Trends

  • Ty21a (Vivotif)

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

  • ViCPS (Typhim Vi)

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

  • Vi-TT (Peda-typhTM)

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

  • Typbar TCV

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global TCV Vaccines Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Introduction

  • Market Share Analysis, 2022 and 2030 (%)

  • Y-o-Y Growth Analysis, 2018 - 2030

  • Segment Trends

  • Public

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

  • UNICEF

  • Tender (Govt.)

  • Private

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global TCV Vaccines Market, By Region, 2017 - 2030, (US$ Mn)

  • Introduction

  • Market Share Analysis, By Region, 2022 and 2030 (%)

  • Y-o-Y Growth Analysis, For Regions, 2018-2030

  • North America

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)

  • U.S.

  • Canada

  • Latin America

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Russia

  • Rest of Europe

  • Asia Pacific

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • ASEAN

  • Rest of Asia Pacific

  • Middle East

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)

  • GCC

  • Israel

  • Rest of Middle East

  • Africa

  • Market Size and Forecast, By Vaccine Brand, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)

  • Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)

  • South Africa

  • Central Africa

  • North Africa

8. Competitive Landscape

  • Heat Map Analysis

  • Market Share Analysis

  • GlaxoSmithKline PLC

  • Company Overview

  • Product Portfolio

  • Financial Overview

  • Key Highlights

  • Market Strategies

  • Sanofi SA

  • Company Overview

  • Product Portfolio

  • Financial Overview

  • Key Highlights

  • Market Strategies

  • Bharat Biotech

  • Company Overview

  • Product Portfolio

  • Financial Overview

  • Key Highlights

  • Market Strategies

  • PT BIO FARMA

  • Company Overview

  • Product Portfolio

  • Financial Overview

  • Key Highlights

  • Market Strategies

  • PaxVax, Inc.

  • Company Overview

  • Product Portfolio

  • Financial Overview

  • Key Highlights

  • Market Strategies

  • Analyst Views

9. Section

For more information about this report visit https://www.researchandmarkets.com/r/1koq83

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting